Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health Mitotic Inhibitor Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentZing HealthPolicy 5858-D

    Medicare Part B Step Therapy Mitotic Inhibitors

    Customize your policy alerts

    Sign up for zing_health Policy 5858-D alerts

    Get alerted when Policy 5858-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of preferred and non-preferred mitotic inhibitor products under Medicare Part B Advanced Biosimilars First. Non-preferred Abraxane requires prior authorization and a clinical exception for treatment of an FDA-approved indication of a preferred product.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Mitotic Inhibitors
    Policy CodePolicy 5858-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization for non-preferred Abraxane and document at least one qualifying clinical exception.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Preferred products
    1Non-preferred product
    365 daysPrior-use lookback
    3Exception pathways

    Non-Preferred Product Clinical Exception

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Non-preferred Product Clinical Exception

    Coverage for a non-preferred product is provided when all of the following are met, including at least one clinical exception.

    Non-preferred product coverage

    • Qualifying clinical exception

      • Prior non-preferred use: The member has received treatment with the non-preferred product in the past 365 days.365 days
      • Preferred product failure or intolerance: The member has a documented inadequate response or intolerable adverse event with either docetaxel or paclitaxel.
      • Clinical avoidance of preferred products: The member has a documented clinical reason to avoid all preferred products.

        Preferred products are docetaxel and paclitaxel.

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required for Non-Preferred Abraxane

    Prior authorization is required for non-preferred Abraxane (paclitaxel, albumin-bound). Submit a request for treatment of an indication that is FDA-approved for the preferred product and include the clinical circumstances supporting an exception to preferred-product therapy.

    • Applies to members requesting treatment with non-preferred Abraxane.
    • Coverage review may consider prior use of a product and clinical circumstances that exclude use of a preferred product.
    • Applicable National Coverage Determinations, Local Coverage Determinations, and Medicare Part B utilization-management programs may also apply.
    Step Therapy

    Preferred Product Step Therapy

    Preferred-product step therapy applies before coverage of non-preferred Abraxane for an indication that is FDA-approved for the preferred product. The preferred products are generic docetaxel and generic paclitaxel; a clinical exception may support Abraxane when the step-therapy criteria are met.

    • Preferred: generic docetaxel.
    • Preferred: generic paclitaxel.
    • Non-preferred: Abraxane (paclitaxel, albumin-bound).
    • Preferred products may still require a clinical prior authorization review.
    Documentation Required

    Document the Clinical Exception

    Document the clinical exception supporting non-preferred Abraxane. The record must establish either prior treatment with Abraxane, an inadequate response or intolerable adverse event with a preferred product, or a clinical reason to avoid all preferred products.

    • Document treatment with Abraxane within the past 365 days, when applicable.
    • Document inadequate response or an intolerable adverse event with either generic docetaxel or generic paclitaxel, when applicable.
    • Document the clinical reason to avoid all preferred products, when applicable.
    Denial Risk

    Denial Risk Without a Qualifying Exception

    Coverage may be denied when the requested treatment is not for an indication that is FDA-approved for the preferred product or when the request does not establish a qualifying clinical exception to preferred-product therapy.

    • No qualifying exception is established by prior non-preferred treatment within the past 365 days.
    • No documented inadequate response or intolerable adverse event with either preferred product.
    • No documented clinical reason to avoid all preferred products.

    Policy Background

    Mitotic inhibitors are antineoplastic agents used to treat malignancies. Under this Medicare Part B Advanced Biosimilars First program, generic docetaxel and generic paclitaxel are the preferred products, while Abraxane (paclitaxel, albumin-bound) is non-preferred. Non-preferred treatment is reviewed through prior authorization and a clinical exception process when circumstances support avoiding a preferred product. Applicable National Coverage Determinations, Local Coverage Determinations, and Medicare Part B utilization management programs continue to apply.

    Initial Therapy for Non-Preferred Product

    Initial Therapy for Non-preferred Product

    Non-preferred product coverage is available when the requested treatment is for an FDA-approved indication of the preferred product and at least one clinical exception is met.

    Initial non-preferred therapy

    • Qualifying clinical exception

      • Prior non-preferred use: The member has received treatment with the non-preferred product in the past 365 days.365 days
      • Preferred product failure or intolerance: The member has a documented inadequate response or intolerable adverse event with either docetaxel or paclitaxel.
      • Clinical avoidance of preferred products: The member has a documented clinical reason to avoid all preferred products.

        Preferred products are docetaxel and paclitaxel.

    Preferred Product Sequence

    StepPreferred productsExceptions allowing non-preferred product
    1Generic docetaxel or generic paclitaxelPrior treatment with the non-preferred product within the past 365 days; documented inadequate response or intolerable adverse event with docetaxel or paclitaxel; or a documented clinical reason to avoid all preferred products.
    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Mitotic Inhibitors
    Policy CodePolicy 5858-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization for non-preferred Abraxane and document at least one qualifying clinical exception.
    SourceLink
    On This Page
    Non-Preferred Product Clinical ExceptionAuthorization, Documentation, and Denial RisksPolicy BackgroundInitial Therapy for Non-Preferred ProductPreferred Product Sequence